Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes

TipRanksNov 14 19:16 · Ratings

Lyra Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Sales Results.

BenzingaNov 14 00:04

BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating

Futu NewsNov 13 19:36 · Ratings

Lyra Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 05:30 · Announcements

Express News | Lyra Therapeutics Q3 EPS USD -0.18

BreakingsNov 13 05:01

Express News | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

BreakingsNov 13 05:01